Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells
- PMID: 8230285
- DOI: 10.1093/jnci/85.23.1937
Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells
Abstract
Background: Our recent findings in vitro in the human colon adenocarcinoma cell line HCT-8 suggest that resistance to fluorouracil (5-FU) in patients with advanced colorectal cancer might be overcome by use of a different treatment schedule.
Purpose: We tested the hypothesis that HCT-8 cells resistant to short-term 5-FU exposure retain sensitivity to continuous exposure and studied interactions between the two schedules.
Methods: HCT-8 cell lines resistant to short-term (pulse) treatment with 5-FU or to continuous exposure were obtained by six exposures to different concentrations of 5-FU for 4 hours or 7 days. We used a monolayer clonogenic assay to determine 5-FU-induced cell kill in resistant HCT-8 cells and sensitive parent cells. Parent cells were exposed to different concentrations of 5-FU for 1, 4, or 24 hours (short term), for 7 days (continuous exposure), or in a combination of both types of schedules. In a study of the mechanism of interaction between short-term and continuous exposure in parent cells, we performed flow cytometric DNA analysis to determine the percentage of cells in S phase and assays of thymidylate synthase inhibition in intact cells and of incorporation of [6-3H)]5-FU nucleotides into nucleic acids.
Results: Sensitive HCT-8 cells became fully resistant to 5-FU within five or six treatments, and low-dose continuous exposure almost immediately produced resistant clones. HCT-8 cells resistant to 5-FU given every 4 hours retained full sensitivity to continuous exposure, suggesting lack of cross-resistance between the two schedules, but cells resistant to continuous exposure were cross-resistant to short-term treatment. Parent cells showed a statistically significant (synergistic) enhancement of the cytotoxic activity for 5-FU exposure for 1 hour (100, 300, or 500 microM) followed by continuous exposure (0.5, 1, or 2 microM) or 4 hours (10, 30, or 60 microM) followed by continuous exposure (1 or 2 microM). Short-term plus continuous exposure produced a marked increase in percentage of S-phase cells, compared with the percentage for each schedule alone. The combination of 1-hour exposure and continuous exposure (1000 and 2 microM, respectively) produced a marked accumulation of cells in S phase at 24 hours (59%), which lasted up to 96 hours (53%). The combination of the two schedules produced only additive enhancement of thymidylate synthase inhibition as well as incorporation of [6-3H]5-FU nucleotides into nucleic acids of HCT-8 cells.
Conclusions: Our findings provide a rationale for the use of bolus 5-FU and continuous infusion 5-FU in sequence.
Implication: We are conducting a clinical trial of bolus methotrexate followed by continuous-infusion 5-FU plus leucovorin.
Similar articles
-
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.Cytotechnology. 1996;19(3):215-9. doi: 10.1007/BF00744215. Cytotechnology. 1996. PMID: 8862009 Clinical Trial.
-
In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells.Clin Cancer Res. 1995 Nov;1(11):1337-44. Clin Cancer Res. 1995. PMID: 9815929
-
Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance.Anticancer Drugs. 1998 Aug;9(7):625-34. doi: 10.1097/00001813-199808000-00008. Anticancer Drugs. 1998. PMID: 9773807
-
Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations.Eur J Cancer. 1999 Mar;35 Suppl 1:S3-8. doi: 10.1016/s0959-8049(99)00041-6. Eur J Cancer. 1999. PMID: 10645207 Review.
-
Biochemical mechanisms in colon xenografts: thymidylate synthase as a target for therapy.Invest New Drugs. 1989 Apr;7(1):59-69. doi: 10.1007/BF00178192. Invest New Drugs. 1989. PMID: 2661484 Review.
Cited by
-
Should we still be using bolus 5-FU prior to infusional regimens in gastrointestinal cancers? A practical review.Int Cancer Conf J. 2021 Nov 24;11(1):2-5. doi: 10.1007/s13691-021-00526-7. eCollection 2022 Jan. Int Cancer Conf J. 2021. PMID: 35127313 Free PMC article. Review.
-
Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.Br J Cancer. 1995 Sep;72(3):669-75. doi: 10.1038/bjc.1995.392. Br J Cancer. 1995. PMID: 7669579 Free PMC article.
-
5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.Invest New Drugs. 2000 Nov;18(4):299-313. doi: 10.1023/a:1006416410198. Invest New Drugs. 2000. PMID: 11081567 Review.
-
Multicentre phase II study of leucovorin plus pharmacokinetic modulating chemotherapy for metastatic colorectal cancer.Oncol Lett. 2010 Jan;1(1):81-85. doi: 10.3892/ol_00000014. Epub 2010 Jan 1. Oncol Lett. 2010. PMID: 22966260 Free PMC article.
-
Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results.Oncologist. 2017 Aug;22(8):886-e79. doi: 10.1634/theoncologist.2017-0206. Epub 2017 Jun 7. Oncologist. 2017. PMID: 28592624 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources